Results of the phase 3 ELOQUENT-2 trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Prof Sagar Lonial at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews